Literature DB >> 7396315

Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression.

D L DeSilvey, A J Moss.   

Abstract

We studied a family with the long QT syndrome. The initial case was in a patient who presented with seizures, ventricular fibrillation, and syncope. After a trial of conventional modalities of treatment including left stellate ganglionectomy, primidone (Mysoline) therapy was initiated. This drug has been successful in suppressing ventricular arrhythmias and shortening the QT interval over a 2-year follow-up period. Two additional family members with QT prolongation have been treated with primidone. During an 8-month follow-up, electrocardiographic and Holter recordings showed shortening of the QT interval.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396315     DOI: 10.7326/0003-4819-93-1-53

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

2.  Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.

Authors:  Rainer Schimpf; Christian Veltmann; Theano Papavassiliu; Boris Rudic; Turgay Göksu; Jürgen Kuschyk; Christian Wolpert; Charles Antzelevitch; Alois Ebner; Martin Borggrefe; Christian Brandt
Journal:  Heart Rhythm       Date:  2012-01-11       Impact factor: 6.343

Review 3.  The QT interval historically treated.

Authors:  H B Burchell
Journal:  Pediatr Cardiol       Date:  1983 Apr-Jun       Impact factor: 1.655

Review 4.  Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms.

Authors:  Rainer Surges; Roland D Thijs; Hanno L Tan; Josemir W Sander
Journal:  Nat Rev Neurol       Date:  2009-08-11       Impact factor: 42.937

5.  Seizure-related cardiac repolarization abnormalities are associated with ictal hypoxemia.

Authors:  Masud Seyal; Franchette Pascual; Chia-Yuan Michael Lee; Chin-Shang Li; Lisa M Bateman
Journal:  Epilepsia       Date:  2011-09-11       Impact factor: 5.864

Review 6.  Long QT syndrome manifesting as pulseless epilepsy.

Authors:  Fuad Abed Abass; Madhukar Shahi; Nirmal Kumar; Moneesha Bhargava; Sangita Gupta; Jacob M Puliyel
Journal:  Indian J Pediatr       Date:  2003-01       Impact factor: 1.967

7.  Enhanced QT shortening and persistent tachycardia after generalized seizures.

Authors:  Rainer Surges; Catherine A Scott; Matthew C Walker
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

Review 8.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Left stellate ganglionectomy for the long Q-T interval syndrome: nine-year follow-up of a patient.

Authors:  N E Strickman; W E Dear
Journal:  Tex Heart Inst J       Date:  1982-06

10.  QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization.

Authors:  J Keirns; A Desai; D Kowalski; C Lademacher; S Mujais; B Parker; M J Schneidkraut; R Townsend; T Wojtkowski; T Yamazaki; M Yen; P R Kowey
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.